Johnson & Johnson ($JNJ) Stock Forecast: Down 1.9% Today

What is Johnson & Johnson?

Johnson & Johnson (JNJ) is a multinational corporation known for its healthcare products, including pharmaceuticals, medical devices, and consumer goods. The company has a strong presence in various segments of the healthcare industry.

Why is Johnson & Johnson going down?

JNJ stock is down 1.9% on Feb 20, 2026 15:35

• The bearish movement in JNJ's stock today could be attributed to the company considering selling its DePuy Synthes Orthopaedics business, a move aimed at enhancing strategic focus and stakeholder value. This potential divestiture might have raised concerns among investors about the impact on JNJ's overall business operations and revenue stream.
• Additionally, the projected growth in the neurosurgery market and fill-finish manufacturing market could have influenced investor sentiment towards JNJ. The competitive landscape in these expanding markets, with key players like Medtronic and other major companies making strategic moves, might have added pressure on JNJ's stock price.
• Overall, the market's reaction to the potential business divestiture and the evolving landscape of the healthcare industry, particularly in neurosurgery and fill-finish manufacturing, likely contributed to the bearish movement in JNJ's stock today.

JNJ Price Chart

JNJ Technical Analysis

JNJ News

Johnson & Johnson MedTech reportedly eyes $20B deal to sell DePuy Synthes ortho unit

Johnson & Johnson MedTech is reportedly considering selling its DePuy Synthes Orthopaedics business, potentially valued at over $20 billion. The move follows J&J's October 2025 announcement to separate the business to enhance strategic focus and stakeholder value, with "big buyout firms" and other medtech companies reportedly interested in the acquisition.

https://www.massdevice.com/johnson-johnson-medtech-eyes-20b-ortho-sale/

Neurosurgery Market Is Going to Boom |Medtronic, Stryker Corporation, Zimmer Biomet, Johnson & Johnson

The global neurosurgery market is projected to grow from USD 4.10 billion in 2026 to USD 5.69 billion by 2033, exhibiting a CAGR of 4.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report by Coherent Market Insights provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.

https://www.openpr.com/news/4398915/neurosurgery-market-is-going-to-boom-medtronic-stryker

Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading

The fill finish manufacturing market is projected to grow from $11.96 billion in 2025 to $21.04 billion by 2030, driven by the increasing demand for advanced therapies, personalized medicine, and outsourcing to CMOs. Key trends include the adoption of automated lines, aseptic processing, and single-use consumables. North America currently holds the largest market share, with Asia-Pacific expected to be the fastest-growing region.

https://finance.yahoo.com/news/fill-finish-manufacturing-market-analysis-101200216.html

Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading

The fill-finish manufacturing market is experiencing significant growth, projected to reach over $21 billion by 2030, driven by increased demand for biopharmaceuticals, cell and gene therapies, and personalized medicine. Key market drivers include advancements in aseptic filling technologies, rising outsourcing to CMOs, and a stronger focus on regulatory compliance. Major players like Johnson & Johnson, AbbVie, and Thermo Fisher Scientific are leading the innovation in this sector, with Asia-Pacific expected to be the fastest-growing region.

https://ca.finance.yahoo.com/news/fill-finish-manufacturing-market-analysis-101200216.html

Robotic Surgical Systems Market Is Going to Boom | Intuitive

Coherent Market Insights has published a new research report on the Robotic Surgical Systems Market, forecasting substantial growth from 2026 to 2033. The report offers a deep dive into market trends, drivers, and competitive landscapes, featuring key players like Intuitive Surgical, Medtronic, and Johnson & Johnson. It provides comprehensive segmentation, regional analysis, and strategic insights for businesses in the healthcare sector.

https://www.openpr.com/news/4398339/robotic-surgical-systems-market-is-going-to-boom-intuitive

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 10.3% Today

DaVita Inc. ($DVA) Stock Forecast: Up 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 5.2% Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.6% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Up 8.9% Today

Intel Corporation ($INTC) Stock Forecast: Up 11.7% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.5% Today

Johnson & Johnson Price History

02.00.2026 - JNJ Stock was up 1.2%

• JNJ's choice to maintain its quarterly dividend at $1.30 per share for the first quarter of 2026 is likely a contributing factor to the positive market sentiment.
• Recent strategic acquisitions, including Halda Therapeutics, and FDA approvals for its medical technologies and treatments have enhanced investor confidence in JNJ's growth prospects.
• Analysts have raised price targets for JNJ following these events, signaling an optimistic outlook for the company's performance and potential future returns.
• Developments related to Pfizer's transformation and AbbVie Inc.'s decrease in stock holdings may have indirectly affected investor interest in JNJ, underscoring the competitive environment in the healthcare and pharmaceutical sector.

13.00.2026 - JNJ Stock was up 2.8%

• JNJ's bullish movement could be attributed to the company's announcement of adding 500 jobs at a new plant in North Carolina, focusing on oncology and neurological treatments. This expansion signifies growth and commitment to domestic manufacturing, which investors view positively.
• The performance of Pfizer in the oncology sector and AbbVie's recent deals with the Trump administration might have also contributed to the positive sentiment in the healthcare sector, indirectly benefiting JNJ as a major player in the industry.
• Investors may be optimistic about the healthcare sector as a whole, considering the focus on research and development, manufacturing investments, and pricing agreements that aim to boost innovation and accessibility to key medicines.
• Overall, the bullish movement in JNJ's stock today could be a reflection of both company-specific developments, such as the new plant expansion, and broader industry trends towards innovation and growth.

20.01.2026 - JNJ Stock was down 1.9%

• The bearish movement in JNJ's stock today could be attributed to the company considering selling its DePuy Synthes Orthopaedics business, a move aimed at enhancing strategic focus and stakeholder value. This potential divestiture might have raised concerns among investors about the impact on JNJ's overall business operations and revenue stream.
• Additionally, the projected growth in the neurosurgery market and fill-finish manufacturing market could have influenced investor sentiment towards JNJ. The competitive landscape in these expanding markets, with key players like Medtronic and other major companies making strategic moves, might have added pressure on JNJ's stock price.
• Overall, the market's reaction to the potential business divestiture and the evolving landscape of the healthcare industry, particularly in neurosurgery and fill-finish manufacturing, likely contributed to the bearish movement in JNJ's stock today.

05.00.2026 - JNJ Stock was down 1.3%

• The bearish movement in JNJ's stock price could be attributed to the halt of a Phase IIb trial for JNJ-95475939, a bispecific antibody for atopic dermatitis, after it failed to meet efficacy expectations. This development might have raised concerns among investors about the company's pipeline and future growth prospects in the dermatology segment.
• Despite being highlighted as one of the AI-powered medical stocks for a strong portfolio in 2026, the setback in the eczema trial could have overshadowed the positive outlook, leading to a bearish sentiment towards JNJ.
• The global rosacea market's projected growth and advancements in AI-powered medical stocks, including JNJ, may have initially created a positive sentiment, but the specific news regarding the failed trial likely had a more immediate and negative impact on the stock price.
• Investors might be closely monitoring JNJ's strategic decisions in dermatology, especially with the focus shifting towards other candidates and acquisitions after the setback with JNJ-95475939, to assess the company's ability to innovate and maintain its competitive edge in the healthcare sector.